secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0001437749-25-019718
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma secures exclusive U.S. commercialization rights to EXXUA (gepirone) for MDD
--------------------------------------------------------------------------------

- Upfront cash payment of $3M; second payment of $3M due 1-year post-launch, increasing to $5M if first-year net sales exceed $35M.
- Royalty on net sales starts at 28%, steps up to 39% when annual net sales surpass $300M; lower tier after trigger at 24.5%-35.5%.
- Milestone payments range from $5M to over $100M per year based on net sales thresholds; 10% royalty on sales above $1B.
- EXXUA is a first-in-class 5HT1a receptor agonist for MDD with no sexual dysfunction label warning; launch targeted for Q4 2025.
- Transaction funded by cash on hand and institutional investors including Nantahala Capital, Stonepine Capital, and Aytu management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925019718/0001437749-25-019718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925019718/aytu20250523c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-019718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer